Skip to main content

Eagle Pharmaceuticals, Inc.

EGRXDelisted Nov 26, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0000827871

Eagle Pharmaceuticals, Inc. was delisted on Nov 26, 2024; its insiders filed their last Form 4 on Mar 1, 2024; 65 institutions reported holding it in 13F filings for Q3 2024, worth $31.9M in total; no superinvestor held it.

Holders of 5% or more of EGRX

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Eagle Pharmaceuticals, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of EGRX
HolderLatest formStakeChangeFirst filedLatest filingFiling
Nantahala Capital Management, LLC13G/A38.08%4.95M shares0.00 ppfrom 38.08%Feb 19, 20252 filingsAug 14, 2025SEC
Union Square Park Capital Management, LLC13G/A11.44%1.49M shares–Feb 14, 20251 filingFeb 14, 2025SEC
Nantahala Capital Partners Limited Partnership13G6.24%810.6K sharesNewFeb 19, 20251 filingFeb 19, 2025SEC
J. Goldman & Co LP13G5.10%667.1K sharesNewAug 14, 20251 filingAug 14, 2025SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

5 Schedule 13D and 13G filings on Eagle Pharmaceuticals, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on EGRX
Filed (ET)FilerFormStakeChangeEvent dateFiling
Aug 14, 20258:08 PM ETJ. Goldman & Co LPand 2 others13G5.10%667.1K sharesNewJun 30, 2025SEC
Aug 14, 20254:42 PM ETNantahala Capital Management, LLCand 2 others13G/A38.08%4.95M shares0.00 ppfrom 38.08%Jun 30, 2025SEC
Feb 19, 20254:32 PM ETNantahala Capital Partners Limited Partnershipand 2 others13G6.24%810.6K sharesNewFeb 16, 2025SEC
Feb 19, 20254:32 PM ETNantahala Capital Management, LLCand 2 others13G/A38.08%4.95M shares–Feb 16, 2025SEC
Feb 14, 20259:01 AM ETUnion Square Park Capital Management, LLCand 3 others13G/A11.44%1.49M shares–Dec 31, 2024SEC
Feb 14, 2022Tarriff Scott13G/AOld format–––SEC
Feb 14, 2022Park West Asset Management LLC13G/AOld format–––SEC
Feb 11, 2022State Street Corp13G/AOld format–––SEC
Feb 10, 2022Janus Henderson Group PLC13G/AOld format–––SEC
Feb 9, 2022Vanguard Group Inc13G/AOld format–––SEC
Jan 27, 202211:00 AM ETBlackRock Inc.13G/AOld format–––SEC
Jan 25, 20223:03 PM ETBlackRock Inc.13G/AOld format–––SEC
Feb 16, 2021Tarriff Scott13G/AOld format–––SEC
Feb 16, 2021Armistice Capital, LLC13G/AOld format–––SEC
Feb 16, 2021Park West Asset Management LLC13G/AOld format–––SEC
Feb 11, 2021Janus Henderson Group PLC13G/AOld format–––SEC
Feb 10, 2021Vanguard Group Inc13G/AOld format–––SEC
Feb 8, 2021State Street Corp13GOld format–New–SEC
Jan 26, 20212:22 PM ETBlackRock Inc.13G/AOld format–––SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Eagle Pharmaceuticals, Inc. shares.

No Form 144 notices for Eagle Pharmaceuticals, Inc. are on file.